BRIEF-Maxcyte Says Enters Strategic Platform License With TG Therapeutics

Reuters
12 Feb
BRIEF-Maxcyte Says Enters Strategic Platform License With TG <a href="https://laohu8.com/S/LENZ">Therapeutics</a>

Feb 12 (Reuters) - MaxCyte Inc MXCT.O:

  • MAXCYTE, INC. MAXCYTE, INC. - MXCR - STRATEGIC PLATFORM LICENSE WITH TG THERAPEUTICS

  • MAXCYTE INC - ENTERS STRATEGIC PLATFORM LICENSE WITH TG THERAPEUTICS

  • MAXCYTE INC - TG THERAPEUTICS OBTAINS RIGHTS TO USE MAXCYTE TECHNOLOGY

Source text: ID:nRSL7610Wa

Further company coverage: MXCT.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10